In pre-clinical xenograft models of ovarian cancer, combination treatment with PARP1 inhibitors and navitoclax reduces tumour burden compared with PARP1 inhibitors alone (Fleury et al., 2019). The gene discussed is PARP1; the disease is neoplasm.